NL-OMON45880
已完成
不适用
CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung cancer, an exploratory study - Biomarkers for tumor response to PD-1 inhibitors
概览
- 阶段
- 不适用
- 干预措施
- 未指定
- 疾病 / 适应症
- Non-small cell lung cancer (NSCLC)
- 发起方
- niversitair Medisch Centrum Groningen
- 入组人数
- 40
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •1\. Histologically confirmed stage IIIB and stage IV NSCLC KRAS positive tumors only.
- •2\. Available tumor tissue sample.
- •3\. Prior palliative radiotherapy must have been completed at least 2 weeks prior to first dose nivolumab.
- •4\. Any line of previous chemotherapy.
- •5\. Nivolumab has to be the treatment that will be started.
- •6\. At least one unidimensionally measurable lesion according to RECIST1\.1 criteria.
- •7\. Life expectancy more than 3 months.
- •8\. ECOG PS 0\-1\.
- •9\. Age18 years and older, both male and female subjects
- •10\. Adequate organ functions
排除标准
- •1\. Previous treatment with PD\-1 or PD\-L1 inhibitor.
- •2\. Lung cancer previously treated for an ALK translocation, EGFR mutation or BRAF mutation
- •3\. Pregnant or lactating women.
- •4\. Patients who are poor medical risks because of non\-malignant disease as well as those with active uncontrolled infection.
- •5\. Patients without plasma sample at baseline (before treatment).
- •6\. Patients are excluded if they have active brain metastases or leptomeningeal metastases. Subjects with brain metastases are eligible if metastases have been treated and there is no magnetic resonance imaging (MRI) evidence of progression for at least 4 weeks after treatment is complete and within 28 days prior to the first dose of nivolumab administration. There must also be no requirement for immunosuppressive doses of systemic corticosteroids (\> 10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug administration.
- •7\. Subjects with carcinomatous meningitis.
- •8\. Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before randomization.
- •9\. Subjects with previous malignancies (except non\-melanoma skin cancers, and the following in situ cancers: bladder, gastric, colon, cervical/dysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.
- •10\. Other active malignancy requiring concurrent intervention.
结局指标
主要结局
未指定
相似试验
尚未招募
不适用
CA209-759: Blood-borne biomarkers for tumor response to Nivolumab in KRAS-mutated non-small cell lung canceron-small cell lung cancer, KRAS mutationNiet-kleincellig longkanker, KRAS mutatieNL-OMON25545niversity Medical Center Groningen40
已完成
不适用
INTENT_Circulating tumor cells as biomarkers for recurrence risk in thermoablatioC22.0Liver cell carcinomaDRKS00016808Klinikum der Universität München, Campus Großhadern100
已完成
不适用
tudy on Biomarkers Using Circulating Tumor Cells When Administering Osimertinib in Patients with EGFR Mutation-positive Lung CancerJPRN-UMIN000032055Toho University50
已完成
不适用
Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinomaC25Malignant neoplasm of pancreasDRKS00023929Allgemein- und Viszeralchirurgie Uniklinik Freiburg14
进行中（未招募）
不适用
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.Prostate CancerMetastatic CancerCastration-resistant Prostate CancerCirculating Tumor CellsNCT03381326Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori104